Načítá se...
Cardiovascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke
AIMS/INTRODUCTION: The cardiovascular (CV) outcomes of vildagliptin – a dipeptidyl peptidase‐4 inhibitor – in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke are unclear. MATERIALS AND METHODS: We analyzed data from the Taiwan National Health Insurance R...
Uloženo v:
| Vydáno v: | J Diabetes Investig |
|---|---|
| Hlavní autoři: | , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6944835/ https://ncbi.nlm.nih.gov/pubmed/31115964 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jdi.13078 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|